PLATEGRA 90mg film-coated tablets medication leaflet

B01AC24 ticagrelor • Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin

Ticagrelor is an antiplatelet medication used to prevent thrombotic events such as myocardial infarction or stroke in patients with acute coronary syndromes or a history of myocardial infarction. It works by reversibly inhibiting P2Y12 receptors on platelets, preventing platelet aggregation.

The medication is taken orally, usually twice daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and not discontinue treatment without consulting their doctor.

Patients should be monitored for potential side effects, such as bleeding, shortness of breath, or dizziness. It is important to inform the doctor of any unusual symptoms or the use of other medications.

Common side effects include bleeding, shortness of breath, and dizziness. In rare cases, severe reactions such as major hemorrhages or bradycardia may occur. Patients should be informed of these risks before starting treatment.

General data about PLATEGRA 90mg

Substance: ticagrelor

Date of last drug list: 10-04-2026

Commercial code: W68872001

Concentration: 90mg

Pharmaceutical form: film-coated tablets

Quantity: 56

Product type: generic

Price: 161.08 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: LABORMED PHARMA S.A. - ROMANIA

Holder: EGIS PHARMACEUTICAL PLC. - UNGARIA

Number: 14486/2022/01

Shelf life: 3 years

Concentrations available for ticagrelor

60mg, 90mg

Compensation lists for PLATEGRA 90mg EGIS

G3 (C1) - Patients with percutaneous interventional procedures

Price

Copayment

Patient

161.08 RON

52.50 RON

108.58 RON